Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive Prostate Cancer in Russian Federation

This study is gathering information about how aggressive metastatic prostate cancer is treated in Russia, and whether certain genetic markers (called HRR mutations) are present in these patients. It is an observational study, meaning researchers will review existing medical records rather than give you a new treatment. **You may be eligible if...** - You are a male aged 18 or older - You were newly diagnosed with aggressive, high-grade (Gleason 8–10) metastatic prostate cancer within the past 2 years - A biopsy tissue sample from your tumor is available - Your HRR mutation status has not yet been tested **You may NOT be eligible if...** - You have participated in any interventional (treatment-testing) clinical trial since being diagnosed with metastatic prostate cancer Talk to your doctor to see if this trial is right for you.